

Literatur zum Artikel

Adipositaschirurgie zur Therapie der nicht-alkoholassozierten Fettlebererkrankung

1. Younossi ZM, Koenig AB, Abdelatif D, et al (2016) Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 64: 73–84
2. Cholaneril G, Patel R, Khurana S, Satapathy SK (2017) Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. *World J Hepatol* 9: 533–543
3. Yeh MM, Brunt EM (2014) Pathological features of fatty liver disease. *Gastroenterology* 147: 754–764
4. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J Hepatol* 56: 1384–1391
5. Roeb E SH, Bantel H, Baumann U, et al (2015) S2k Leitlinie Nicht-alkoholische Fettlebererkrankungen. *Z Gastroenterol* 53: 668–723
6. Degasperis E, Colombo M (2016) Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. *Lancet Gastroenterol Hepatol* 1: 156–164
7. Chalasani N, Younossi Z, Lavine JE, et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 55: 2005–2023
8. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al (2016) Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. *Hepatology* 63: 827–838
9. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 10: 330–344
10. Chalasani N, Younossi Z, Lavine JE, et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 67: 328–357
11. Gerber L, Otgonsuren M, Mishra A, et al (2012) Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. *Aliment Pharmacol Ther* 36: 772–781
12. Targher G, Bertolini L, Padovani R, et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 30: 1212–1218
13. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 34: 274–285
14. Ekstedt M, Franzén LE, Mathiesen UL, et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 44: 865–873
15. Musso G, Gambino R, Cassader M, Pagano G (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 43: 617–649
16. Kim D, Kim WR, Kim HJ, Therneau TM (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology* 57: 1357–1365
17. Byrne CD, Targher G (2015) NAFLD: a multisystem disease. *J Hepatol* 62: 547–64
18. Greten TF, Malek NP, Schmidt S, et al (2013) Diagnose und Therapie des hepatozellulären Karzinoms. *Z Gastroenterol* 51: 1269–1326
19. Zhou JH, Cai JJ, She ZG, Li HL (2019) Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. *World J Gastroenterol* 25: 1307–1326
20. Wong VW, Vergniol J, Wong GL, et al (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 51: 454–462
21. Myers RP, Pomier-Layrargues G, Kirsch R, et al (2012) Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. *Hepatology* 55: 199–208
22. Grandison GA, Angulo P (2012) Can NASH be diagnosed, graded, and staged noninvasively? *Clin Liver Dis* 16: 567–585
23. Ooi GJ, Burton PR, Bayliss J, et al (2019) Effect of body mass index, metabolic health and adipose tissue inflammation on the severity of non-alcoholic fatty liver disease in bariatric surgical patients: a prospective study. *Obes Surg* 29: 99–108
24. Perk J, De Backer G, Gohlke H, et al (2013) European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *G Ital Cardiol (Rome)* 14: 328–392
25. Romero-Gomez M, Zelber-Sagi S, Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 67: 829–846
26. Eshraghian A (2017) Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. *World J Gastroenterol* 23: 7495–7504
27. Leoni S, Tovoli F, Napoli L, et al (2018) Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World J Gastroenterol* 24: 3361–3373
28. Roeb E, Geier A (2019) Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments. *Z Gastroenterol* 57: 508–517
29. Hallsworth K, Fattakhova G, Hollingsworth KG, et al (2011) Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. *Gut* 60: 1278–1283
30. Thoma C, Day CP, Trenell MI (2012) Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. *J Hepatol* 56: 255–266
31. Colquitt JL, Pickett K, Loveman E, Frampton GK (2014) Surgery for weight loss in adults. *Cochrane Database Syst Rev* CD003641
32. Runkel N, Colombo-Benkmann M, Hüttl TP, et al (2011) Evidence-based German guidelines for surgery for obesity. *Int J Colorectal Dis* 26: 397–404
33. Gloy VL, Briel M, Bhatt DL, et al (2013) Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ* 347: f5934
34. Sjöström L (2008) Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. *Int J Obes (Lond)* 32 (Suppl 7):S93–7
35. de Jonge C, Rensen SS, Koek GH, et al (2013) Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 11: 1517–1520
36. Caiazzo R, Lassailly G, Leteurtre E, et al (2014) Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. *Ann Surg* 260: 893–898
37. Elnahas A, Nguyen GC, Okrainec A, et al (2014) The effect of underlying liver disease on short-term outcomes following bariatric surgery. *Surg Endosc* 28: 2708–2712
38. Cazzo E, Jimenez LS, Pareja JC, Chaim EA (2015) Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. *Obes Surg* 25: 982–985
39. Lassailly G, Caiazzo R, Buob D, et al (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. *Gastroenterology* 149: 379–388
40. Stratopoulos C, Papakonstantinou A, Terzis I, et al (2005) Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. *Obes Surg* 15: 1154–1160
41. Glass LM, Dickson RC, Anderson JC, et al (2015) Total body weight loss of >10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. *Dig Dis Sci* 60:1024–1030

42. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE (2004) Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. *Hepatology* 39: 1647–1654
43. Tai CM, Huang CK, Hwang JC, et al (2012) Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. *Obes Surg* 22: 1016–1021
44. Vargas V, Allende H, Lecube A, et al (2012) Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. *World J Hepatol* 4: 382–388
45. Rubino F, Nathan DM, Eckel RH, et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Surg Obes Relat Dis* 12: 1144–1162
46. Müller BP BA, Straub BK, Israel B, et al (2016) Gastric bypass increases FGF-19 and FGF-21 and improves steatohepatitis in metabolically sick patients with diabetes mellitus Type 2 and low-BMI <35 kg/m². *IFSO World congress, Rio de Janeiro*
47. Yang B, Yang HP, Ward KK, et al (2016) Bariatric surgery and liver cancer in a consortium of academic medical centers. *Obes Surg* 26: 696–700
48. Klebanoff MJ, Corey KE, Chhatwal J, et al (2017) Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. *Hepatology* 65: 1156–1164
49. DGAV (2018) S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. *AWMF online*
50. Hillenbrand A, Kiebler B, Schwab C, et al (2015) Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. *BMC Res Notes* 8: 290
51. Mosko JD, Nguyen GC (2011) Increased perioperative mortality following bariatric surgery among patients with cirrhosis. *Clin Gastroenterol Hepatol* 9: 897–901
52. Shimizu H, Phuong V, Maia M, et al (2013) Bariatric surgery in patients with liver cirrhosis. *Surg Obes Relat Dis* 9: 1–6
53. Jan A, Narwaria M, Mahawar KK (2015) A systematic review of bariatric surgery in patients with liver cirrhosis. *Obes Surg* 25: 1518–1526
54. McCarty TR, Echouffo-Tcheugui JB, Lange A, et al (2018) Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004–2012. *Surg Obes Relat Dis* 14: 74–80
55. Nickel F, Tapking C, Benner L, et al (2018) Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up: BariScan study. *Obes Surg* 28: 1342–1350
56. Cabre N, Luciano-Mateo F, Fernandez-Arroyo S, et al (2019) Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. *Metabolism* 99: 81–89
57. Killackey M, Zhang R, Sparks K, et al (2010) Challenges of abdominal organ transplant in obesity. *South Med J* 103: 532–540
58. Dziodzio T, Biebl M, Ollinger R, et al (2017) The role of bariatric surgery in abdominal organ transplantation –the next big challenge? *Obes Surg* 27: 2696–2706
59. Ferrer Marquez M, Carvia Pousaille C, Velasco Albendea J, et al (2009) Influence of bariatric surgery on the non-alcoholic liver steatosis. A histological evaluation (Spanisch). *Cir Esp* 86: 94–100
60. Vespasiani-Gentilucci U, Vorini F, Carotti S, et al (2017) Hepatic complications of bariatric surgery : the reverse side of the coin. *Acta Gastroenterol Belg* 80: 505–513
61. Eilenberg M, Langer FB, Beer A, et al (2018) Significant liver-related morbidity after bariatric surgery and its reversal – a case series. *Obes Surg* 28: 812–819
62. Billeter AT, Senft J, Gotthardt D, et al (2016) Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass? – a controlled matched pair study of 34 patients. *Obes Surg* 26: 1867–1874
63. Kalinowski P, Paluszkiwicz R, Ziarkiewicz-Wroblewska B, et al (2017) Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-y gastric bypass versus sleeve gastrectomy: a secondary analysis of a randomized clinical trial. *Ann Surg* 266: 738–745